SCHEMBL13629785

SCHEMBL13629785

C1=Cc2c(oc3ccc(-c4ccc5c6ccc(-c7ccc8oc9ccccc9c8c7)cc6c6c7cc(-c8ccc9oc%10ccccc%10c9c8)ccc7c7ccc(-c8ccc9oc%10ccccc%10c9c8)cc7c6c5c4)cc23)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.37
▸ KMT2A Q03164 4/20 0.37
▸ MAPT P10636 4/20 0.37
▸ NPC1 O15118 4/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ RAB9A P51151 3/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ PLA2G2A P14555 3/20 0.36
▸ PLA2G4A P47712 3/20 0.36
▸ PLA2G10 O15496 1/20 0.34
▸ AHR P35869 2/20 0.34
▸ CASP3 P42574 1/20 0.33
▸ SENP7 Q9BQF6 1/20 0.33
▸ SENP6 Q9GZR1 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.32
▸ HSP90AB1 P08238 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15889121 0.91 MAPT (0.40) MEN1KMT2AMAPTNPC1SMN1; SMN2
SCHEMBL21336983 0.91 PLA2G2A (0.40) MEN1KMT2AMAPTNPC1SMN1; SMN2
SCHEMBL14052191 0.90 MAOA (0.39) MEN1KMT2AMAPTNPC1SMN1; SMN2
SCHEMBL21426315 0.90 PLA2G2A (0.44) MEN1KMT2AMAPTNPC1SMN1; SMN2
SCHEMBL26010105 0.87 MAPT (0.39) MEN1KMT2AMAPTNPC1SMN1; SMN2
SCHEMBL12698473 0.87 ALOX5 (0.36) MEN1KMT2AMAPTNPC1SMN1; SMN2
SCHEMBL24031899 0.86 MAPT (0.38) MEN1KMT2AMAPTNPC1SMN1; SMN2
SCHEMBL13777035 0.85 PLA2G2A (0.36) MEN1KMT2AMAPTNPC1SMN1; SMN2
SCHEMBL20079963 0.85 PLA2G2A (0.34) MEN1KMT2AMAPTNPC1SMN1; SMN2
SCHEMBL10131282 0.83 PLA2G2A (0.36) MEN1KMT2AMAPTNPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090273278-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-11-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090273278-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same OCIAD1, OCIAD2, ORMDL3 MEN1 3925/4885KMT2A 3177/4885MAPT 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback